U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454122) titled 'CD5CAR-NK Cells for Refractory Invasive Mold Disease' on March 02.
Brief Summary: CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD).
The study population consists of patients aged >=18 years with refractory mold infections.
The number of patients treated will be 10. This is a dose-escalation study including 3 cohorts.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Fungal Infection
Intervention:
GENETIC: CD5CAR-CBNK
Allogeneic natural killer (NK) cells derived from umbilical cord blood (CB) units,...